Close menu




April 28th, 2022 | 13:00 CEST

BioNTech share price about to double? Varta and Meta Materials with newsflow, or not

  • Biotechnology
  • Technology
Photo credits: metamaterial.com

Those who are currently betting on rising prices on the stock market need strong nerves. But some companies are worth a closer look. Among others, this applies to BioNTech. The Company is facing important deadlines, continues to earn billions with its Corona vaccine and has an attractive product pipeline. The analysts at Berenberg, for example, see doubling potential after the stock has bottomed out. Meta Materials has also formed a bottom formation, and at the same time, there was positive newsflow from the developer of revolutionary products. Varta shareholders have been hoping for this for some time, but in vain. The share is battered, and even the current financial injection cannot change that.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , Meta Materials Inc. | US59134N1046 , VARTA AG O.N. | DE000A0TGJ55

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Meta Materials: Science fiction becomes reality

    Metamaterials seem to turn physics on its head and have remarkable properties. They have nanostructures and can, for example, guide light around an object, making it invisible. And there are not only optical metamaterials. There are also acoustic ones that manipulate sound, thermal ones in which heat conduction is directed, and mechanical metamaterials, for example, solids that behave like liquids. It sounds like science fiction, but actual products are now emerging. One of the pioneers in this field is Meta Materials.

    The Canadians have developed a technology platform that uses artificial intelligence to produce high-performance functional materials and nanocomposites. The potential applications of the products are enormous - from electric vehicles to the Internet of Things, renewable energies, medicine and aerospace. In 2021, Meta Materials turned over USD 4.1 million, 264% more than the previous year. In addition, research and development is underway - 163 patents have been granted, and another 106 have been filed - and production capacity is being expanded. The Company is not yet making a profit, accordingly. Nor has there been anything to gain yet with the NASDAQ-listed stock. After peaking at USD 21.76 last summer, the share price fell sharply to USD 1.23. In the meantime, a bottom seems to have been found because, operationally, things are happening.

    In April, Meta went from strength to strength. First, the acquisition of Plasma App Ltd. was announced. The purchase price of 20 million Canadian dollars (CAD) was paid in shares at CAD 1.86. The acquisition is expected to increase production capacity significantly, increasing speed and reducing costs. In addition, Plasma App has an interesting technology in the field of battery materials. Meta has also received an interesting order from a central bank for CAD 2.2 million - Meta's subsidiary Nanotech Security is developing a unique security feature for cash. Meta Materials is also stepping on the gas in terms of personnel. A new experienced executive vice president has come on board to head the engineering and electro-optical and infrared systems department.

    In addition, George Francis, a manager with over twenty-five years of professional experience, has been recruited for the newly created position of Chief Information Officer. He will not only look after IT architecture and cybersecurity but will also look into the potential monetization of the data that Meta's new products are likely to generate. The stock has yet to react to the positive news flow, but that is likely only a matter of time.

    BioNTech on the verge of doubling in price?

    Shareholders of BioNTech have had little reason to rejoice in recent weeks. However, at least a bottoming out seems to be underway for the German biotech startup's stock. Previously, BioNTech had reported convincing figures and announced a share buyback and a special dividend. There should be potential for price swings in the coming weeks. The release of clinical data on the safety, tolerability and efficacy of a vaccine tailored to the Omicron variant is eagerly awaited. On May 9, BioNTech will also report on its operating performance for the first quarter of 2022. Most recently, Berenberg had also commented positively on BioNTech. Although the analysts have reduced the price target from USD 400 to USD 350, this would still mean more than a doubling of the price. Accordingly, they recommend the share as a buy. The Corona vaccine would continue to bring billions into the coffers, the product pipeline for infectious diseases is well filled, and the share is accordingly undervalued.

    Varta: 250 million promissory note for growth

    The Varta share is having a hard time bottoming out. This week, for example, it fell below the EUR 90 mark again. On March 31, the Group presented figures for the past fiscal year. There is currently a lack of positive impetus. Initially, the annual figures were not convincing. Varta increased sales by 3.8% to EUR 902.9 million in the past fiscal year. Adjusted EBITDA increased by 17.4% to EUR 282.9 million. In the current year, sales are expected to be between EUR 950 million and EUR 1 billion and EBITDA is expected to fall slightly.

    However, the Company said the forecast is fraught with question marks due to Russia's war of aggression and the impact of Corona on customers. The hope for management and shareholders is the V4Drive for use in electric cars. To this end, Varta has raised fresh capital and placed a EUR 250 million promissory note loan. Varta CTO Rainer Hald: "The plan is to use the money to expand our lithium-ion business. One focus will be on building up production capacities of the large-format round cell. In addition, the capacities of the small-format cells will also be further expanded." However, concrete customers or partners in the field of electromobility are still not forthcoming. Most recently, Warburg Research reduced its price target for Varta from EUR 113 to EUR 110.


    Strong nerves are needed on the stock market at the moment. But stocks like BioNTech, Varta and Meta Materials have future potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on March 16th, 2026 | 09:05 CET

    BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors?

    • cleantech
    • biochar
    • Biotechnology
    • Automotive

    A cleantech growth story with takeover potential is currently available for only around CAD 35 million. CHAR Technologies is benefiting from rising oil and gas prices thanks to its technology. If the stock fails to move higher, a strategic partner could step in. Is BioNTech a takeover candidate? Until last week, the answer would likely have been a clear no. But since the announcement that the founders are stepping down, almost anything seems possible. And there is another factor in its favor. To avoid being swallowed by a major defense contractor, Steyr Motors aims to grow aggressively - both organically and through acquisitions. Analysts believe the company could double its revenue and recommend buying the stock.

    Read

    Commented by Fabian Lorenz on March 12th, 2026 | 07:25 CET

    Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Takeover

    First, the positive news: Vidac Pharma's drug candidate VDA-1102 was recently used in a compassionate treatment case in connection with a girl's third brain surgery. Following the treatment, the patient's condition improved significantly. In addition, the Vidac platform is now being tested beyond oncology. 2026 could mark a potential breakthrough year for the company and its stock. It was a different story this week for BioNTech, whose shares suffered a sharp setback. The rather mixed results for 2025 and the cautious outlook for the current year likely played only a limited role. More troubling for shareholders is likely the impending departure of the founding couple. This raises the question: Could BioNTech become a takeover target? There were also long faces at Evotec this week. The company's restructuring program has failed to convince the market, and the stock has slipped below an important technical support level.

    Read

    Commented by Nico Popp on March 12th, 2026 | 07:15 CET

    Nuclear power comeback in the EU! Solid returns with American Atomics, Amazon, and E.ON

    • nuclear
    • Energy
    • SMR
    • Technology
    • AI
    • Uranium

    Since the EU nuclear summit in Paris a few days ago, it has become clear that nuclear energy is once again socially acceptable in Europe. At the meeting, the European Commission described the former move away from nuclear power as a strategic mistake and launched a comprehensive offensive for small modular reactors (SMRs). According to the EU strategy, an SMR capacity of up to 53 GW is to be built up by 2050 in order to reduce the persistently high electricity prices and stop the impending exodus of industry. At the same time, a new factor is driving global electricity demand: artificial intelligence (AI). The International Energy Agency (IEA) predicts that the share of nuclear and renewable energy in the global electricity mix will rise to 50% by 2030. Tech giants such as Amazon increasingly want to satisfy the energy hunger of AI data centers themselves. E.ON is also likely to benefit from this historic strategic shift by operating stable grids. However, at the source of the new boom is the up-and-coming exploration company American Atomics, which is searching for urgently needed uranium and closing a strategic gap in the supply chain. We highlight where investors can find the most attractive opportunities.

    Read